Long-term outcome of low-grade oligodendroglioma and mixed glioma
Abstract
Background: Low-grade oligodendrogliomas and mixed gliomas can be indolent and remain unchanged for years. Optimal timing and effectiveness of initial treatment is uncertain and therapy can be associated with toxicity.
Methods: Retrospective review of patients diagnosed between 1979 and 1997 with low-grade oligodendroglioma or mixed glioma. Time to progression, survival, prognostic factors, and treatment toxicities were evaluated.
Results: A total of 106 patients (77 oligodendroglioma, 29 mixed glioma) were identified; median age was 36.7 years. Initial presenting symptoms were seizures in 76 (72%) and headache in 11 (10%); tumor was diagnosed as an incidental finding in five patients. Tumor progression was diagnosed in 72 patients (68%). Overall median time to progression (MTTP) was 5.0 years (range 0.5 to 14.2). Median overall survival (OS) was 16.7 years. No prognostic factors reached statistical significance. MTTP and OS were not significantly affected by treatment. Of 62 patients who received radiation therapy, 9 (15%) developed radiation necrosis and 13 developed radiation therapy–related cognitive changes, requiring ventriculoperitoneal shunting in six. Significant myelosuppression was seen in 35 of 76 (46%) patients treated with chemotherapy.
Conclusions: Low-grade oligodendroglioma and mixed glioma have a long median overall survival. There were no apparent differences in either immediate versus deferred treatment or choice of initial therapy on disease-free or overall survival. Chemotherapy was associated with significant acute toxicity in almost one half of patients; radiation therapy produced late neurotoxicity in one third, justifying deferred treatment until clinically necessary.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Russell DS, Rubenstein LJ, eds. Pathology of tumors of the central nervous system. Baltimore:Williams and Wilkins, 1989.
2.
Mork SJ, Lindegaard KF, Halvorsen TB. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985;63:881–889.
3.
Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 1998;88:1–10.
4.
Lindegaard KF, Mork SJ, Eide GE, et al. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987;67:224–230.
5.
Chin HW, Hazel JJ, Kim TH, Webster JH. Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 1980;45:1458–1466.
6.
Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992;76:428–434.
7.
Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994;35:1018–1034.
8.
Recht L, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 1992;31:431–436.
9.
Barker FG, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936–941.
10.
Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436–440.
11.
Wallner KE, Gonzales M, Sheline GE. Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 1988;68:684–688.
12.
Bullard DE, Rawlings CE, Phillips B, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987;60:2179–2188.
13.
Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994;30:567–573.
14.
Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15:1294–1301.
15.
Reedy DP, Bay JW, Hahn JF. Role of radiation therapy in the treatment of cerebral oligodendroglioma: an analysis of 57 cases and a literature review. Neurosurgery 1983;13:499–503.
16.
Shaw EG, Scheithauer BW, Gilbertson DT, et al. Postoperative radiotherapy of supratentorial low-grade gliomas. Int J Radiat Oncol Biol Phys 1989;16:663–668.
17.
Whitton AC, Bloom HJG. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys 1990;18:783–786.
18.
Nijjar TS, Simpson WJ, Gadalla T, McCartney M. Oligodendroglioma. The Princess Margaret Hospital experience (1958–1984). Cancer 1993;71:4002–4006.
19.
Sun ZM, Genka S, Shitara N, Akanuma A, Takakura K. Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 1988;22:886–891.
20.
Shimizu KT, Tran LM, Mark RJ, Selch MT. Management of oligodendrogliomas. Radiology 1993;186:569–572.
21.
Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36:549–556.
22.
Karim AB, Cornu P, Bleehen N, et al. Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but not overall survival: preliminary results of an EORTC/MRC randomized phase III study. Proc Am Soc Clin Oncol 1998;17:400a. Abstract.
23.
Shaw EG, Arussell R, Scheithauer BW, et al. A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a NCCTG-RTOG-ECOG study. Proc Am Soc Clin Oncol 1998;17:401a. Abstract.
24.
Curran D, Kiebert GM, Aaronson F, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response. Proc Am Soc Clin Oncol 1998;17:379a. Abstract.
25.
Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360–364.
26.
Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573–574.
27.
Paleologos NA, Vick NA, Kachoris JP. Chemotherapy for low-grade oligodendrogliomas? Ann Neurol 1994;36:294–295.
28.
Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992;31:78–82.
29.
Glass J, Hochberg FH, Gruber ML, et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992;76:741–745.
30.
Cairncross G, Macdonald DR, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:2013–2021.
31.
Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996;46:203–207.
32.
Soffietti R, Chio A, Moccellini C, et al. Response of oligodendroglial tumors to PCV chemotherapy. Neurology 1994;44:309–310.
33.
Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998;43:1066–1073.
34.
Perry JR. Early seizure control but delayed radiographic responses following chemotherapy for low grade oligodendroglioma. Neurology 1999;52:A423. Abstract.
35.
Soffietti R, Ruda RR, Borgognone M, Schiffer D. Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas and oligoastrocytomas. Neurology 1999;52:A423–A424. Abstract.
36.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
37.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–170.
38.
Cox DR, Oakes D. Analysis of survival data. New York:Chapman & Hall, 1990.
39.
Peterson K, Rosenblum MK, Powers JM, Alvord E, Walker RW, Posner JB. Effect of brain irradiation on demyelinating lesions. Neurology 1993;43:2105–2112.
40.
Cairncross JG, Laperriere NJ. Low-grade glioma. To treat or not to treat? Arch Neurol 1989;46:1238–1239.
41.
Shapiro WR. Low-grade gliomas: when to treat? Arch Neurol 1992;31:437–438.
42.
Levin VA. Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. Curr Opin Oncol 1996;8:175–177.
43.
Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–1479.
44.
Buckner JC, Smith JS, Nelson DF, et al. Phase II trial of procarbazine, CCNU, and vincristine (PCV) as initial therapy in patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy results and associations with chromosome 1p and 19q loss. Proc Amer Soc Clin Oncol 1999;18:140a. Abstract.
Information & Authors
Information
Published In
Copyright
© 2000.
Publication History
Received: November 2, 1999
Accepted: December 20, 1999
Published online: April 11, 2000
Published in print: April 11, 2000
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Radiation-Induced Brain Injury: Age Dependency of Neurocognitive Dysfunction Following Radiotherapy, Cancers, 15, 11, (2999), (2023).https://doi.org/10.3390/cancers15112999
- Written language preservation in glioma patients undergoing awake surgery: The value of tailored intra‐operative assessment, Journal of Neuropsychology, (2023).https://doi.org/10.1111/jnp.12349
- SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma, World Neurosurgery, 178, (e595-e640), (2023).https://doi.org/10.1016/j.wneu.2023.07.134
- Neurophysiologic cut off values for safe resection of patients with supratentorial gliomas, Acta Neurochirurgica, (2023).https://doi.org/10.1007/s00701-023-05865-3
- Incidental Brain Tumors, Incidental Findings of the Nervous System, (71-87), (2023).https://doi.org/10.1007/978-3-031-42595-0_7
- Oligodendroglioma, Brain Tumors, (39-49), (2023).https://doi.org/10.1007/978-3-031-41413-8_3
- Malignant Glioma, Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2, (1-30), (2023).https://doi.org/10.1007/978-3-031-23705-8_1
- Sociocognitive Functioning and Psychosocial Burden in Patients with Brain Tumors, Cancers, 14, 3, (767), (2022).https://doi.org/10.3390/cancers14030767
- Influences on cognitive outcomes in adult patients with gliomas: A systematic review, Frontiers in Oncology, 12, (2022).https://doi.org/10.3389/fonc.2022.943600
- Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients, Frontiers in Oncology, 12, (2022).https://doi.org/10.3389/fonc.2022.827897
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.